Analog Devices, Inc. vs Smith & Nephew plc — how do they compare? Analog Devices, Inc. trades at $395.35 (market cap $187.67B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Analog Devices, Inc. is far larger — about 15× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| ADI | SNN | |
|---|---|---|
Market Cap | $187.67B | $12.54B |
Sector | Technology | Health |
52-Week High | $445.48 | $38.70 |
52-Week Low | $225.20 | $28.73 |
Enterprise Value | $192.92B | $15.57B |
Dividend Yield | 1.14% | 2.65% |
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $383.93, down 1.54% on the day, with a bullish technical signal from moving averages. The company demonstrates strong profitability with a 26.01% net income margin and has beaten earnings estimates for the last three quarters. Recent news highlights institutional buying and a spin-off of ADI Global Distribution, completed August 4, 2026, as per a Business Wire report.
The outlook is positive, supported by a strong analyst consensus with a $472.29 price target and no sell ratings. Key opportunities include consistent earnings outperformance and exposure to semiconductor sector growth. Risks involve high valuation multiples and potential market volatility impacting the stock's premium pricing.
No Aura AI signal available yet.
Trailing returns across standard periods
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →